Imperial College London
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Imperial College London
Asia Deal Watch: Hanmi Licenses Greater China Rights To Dry AMD Injectable To AffaMed
Plus deals involving GC Cell/Rivaara Immune, Sperogenix/Santhera, EOFlow/Zihipp, Grand/ITM, Tasly/Sutro, LegoChem/Iksuda, Nuance/Aerogen, Frontier/AffiRiS and Piramal/Yapan.
Apollo’s Next Steps: Apply Learnings From Prior Hub-And-Spoke Entities
Apollo’s $145m financing will help advance its 15-plus candidate portfolio into clinical development. With Patient Square leading the round, its expertise with BridgeBio and co. will help guide Apollo’s evolution.
Tech Transfer Roundup: NCI Licenses Leukemia, Brain Cancer Candidates To Vor, Connectyx
NIH’s National Cancer Institute licensed two experimental cancer therapies in the past month to biopharma firms, leading a heavy slate of cancer-focused tech transfer deal-making.
Tech Transfer Roundup: Mustang Licenses St. Jude’s Gene Therapy For Bubble Boy Disease
Fortress Biotech’s subsidiary will add the lentiviral gene therapy now in pair of Phase I/II trials to its pipeline. RXi partners with Karolinska to advance its self-delivering RNAi technology, while Avalon enlists Weill Cornell to enhance its CAR-T capabilities.
- Academic and Research Institutions
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.